These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24456077)

  • 1. Potency prediction of β-secretase (BACE-1) inhibitors using density functional methods.
    Roos K; Viklund J; Meuller J; Kaspersson K; Svensson M
    J Chem Inf Model; 2014 Mar; 54(3):818-25. PubMed ID: 24456077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of amidine-based brain penetrant BACE1 inhibitors.
    Oehlrich D; Prokopcova H; Gijsen HJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story.
    Stamford A; Strickland C
    Curr Opin Chem Biol; 2013 Jun; 17(3):320-8. PubMed ID: 23683349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
    Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
    Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
    Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
    Edwards PD; Albert JS; Sylvester M; Aharony D; Andisik D; Callaghan O; Campbell JB; Carr RA; Chessari G; Congreve M; Frederickson M; Folmer RH; Geschwindner S; Koether G; Kolmodin K; Krumrine J; Mauger RC; Murray CW; Olsson LL; Patel S; Spear N; Tian G
    J Med Chem; 2007 Nov; 50(24):5912-25. PubMed ID: 17985862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors.
    Niu Y; Gao H; Xu F; Wang C; Liu P; Yang G; Sun Q; Xu P
    Chem Biol Drug Des; 2012 Nov; 80(5):775-80. PubMed ID: 22882897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress toward the discovery and development of efficacious BACE inhibitors.
    Durham TB; Shepherd TA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-organizing molecular field analysis on human β-secretase nonpeptide inhibitors: 5, 5-disubstituted aminohydantoins.
    Li Z; Zhou M; Wu F; Li R; Ding Z
    Eur J Med Chem; 2011 Jan; 46(1):58-64. PubMed ID: 21093114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
    Thompson LA; Shi J; Decicco CP; Tebben AJ; Olson RE; Boy KM; Guernon JM; Good AC; Liauw A; Zheng C; Copeland RA; Combs AP; Trainor GL; Camac DM; Muckelbauer JK; Lentz KA; Grace JE; Burton CR; Toyn JH; Barten DM; Marcinkeviciene J; Meredith JE; Albright CF; Macor JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6909-15. PubMed ID: 21974952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating scoring functions for docking and designing beta-secretase inhibitors.
    Katharine Holloway M; McGaughey GB; Coburn CA; Stachel SJ; Jones KG; Stanton EL; Gregro AR; Lai MT; Crouthamel MC; Pietrak BL; Munshi SK
    Bioorg Med Chem Lett; 2007 Feb; 17(3):823-7. PubMed ID: 17107793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS).
    Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J
    ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
    Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
    Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket.
    Jennings LD; Cole DC; Stock JR; Sukhdeo MN; Ellingboe JW; Cowling R; Jin G; Manas ES; Fan KY; Malamas MS; Harrison BL; Jacobsen S; Chopra R; Lohse PA; Moore WJ; O'Donnell MM; Hu Y; Robichaud AJ; Turner MJ; Wagner E; Bard J
    Bioorg Med Chem Lett; 2008 Jan; 18(2):767-71. PubMed ID: 18068983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for dimeric BACE-mediated APP processing.
    Jin S; Agerman K; Kolmodin K; Gustafsson E; Dahlqvist C; Jureus A; Liu G; Fälting J; Berg S; Lundkvist J; Lendahl U
    Biochem Biophys Res Commun; 2010 Feb; 393(1):21-7. PubMed ID: 20097169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
    Zhu Z; Sun ZY; Ye Y; Voigt J; Strickland C; Smith EM; Cumming J; Wang L; Wong J; Wang YS; Wyss DF; Chen X; Kuvelkar R; Kennedy ME; Favreau L; Parker E; McKittrick BA; Stamford A; Czarniecki M; Greenlee W; Hunter JC
    J Med Chem; 2010 Feb; 53(3):951-65. PubMed ID: 20043696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep neural network affinity model for BACE inhibitors in D3R Grand Challenge 4.
    Wang B; Ng HL
    J Comput Aided Mol Des; 2020 Feb; 34(2):201-217. PubMed ID: 31916049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of pyrrolidine-based β-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.
    Stachel SJ; Steele TG; Petrocchi A; Haugabook SJ; McGaughey G; Katharine Holloway M; Allison T; Munshi S; Zuck P; Colussi D; Tugasheva K; Wolfe A; Graham SL; Vacca JP
    Bioorg Med Chem Lett; 2012 Jan; 22(1):240-4. PubMed ID: 22130130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.